Development of afucosylated monoclonal antibodies with enhanced effector functions to combat malaria

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

• FcRider-based Expression and Delivery of Stable Env Immunogens for HIV Vaccines
• SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES
• Nanoparticle Delivery of HIV Env Trimer for Inducing Somatic Hypermutation and bNAb
• The purpose of this contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing HIV envelope/antigen expression in mammalian cell lines and to accelerate development of purification platforms in a cGMP manufacturing se
• Development of Anti Diphtheria Toxin Therapeutic Anitbodies for Use in Humans

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

• SBIR Topic 109: Development of Monoclonal Antibody- Mediated Interventions to Combat Malaria
• Development of monoclonal antibody-mediated interventions to combat malaria
• Development of monoclonal antibody-mediated interventions to combat malaria
• Multi-path DCS as a novel non-invasive treatment for amyotrophic lateral sclerosis
• SBIR TOPIC 109, PHASE I - TRANSCATHETER TRILEAFLET TRICUSPID SUTURE REPAIR SYSTEM

Research funding history

8 SBIR/STTR records share this UEI (2011–2022). Reported award amounts total $3,699,909. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards